MedCity INVEST PharmaTechMedCity INVEST PharmaTech

Scott Snyder

Co-Founder & CEO,
Geneticure

@scottlastname

Scott co-founded Geneticure in 2015 with the goal of using an individual’s genetics to eliminate avoidable costs and outcomes from chronic diseases, beginning with hypertension (high blood pressure).

The Geneticure scientific approach is to lead with clinical evidence, developing tests that are disease-specific and appreciate the genetics of integrative physiology within target organ systems and pathways.

The Geneticure team from Mayo Clinic, has completed four clinical trials demonstrating that their pharmacogenomics panel can better control hypertension vs. standard of care, with 36% lower blood pressure, at half the cost. The Geneticure for Hypertension Pharmacogenomic Panel is the first of its kind to use multiple gene variants that have been weighted according to their impact on blood pressure response and include integration across organ systems and medication response.

The patented test was formulated using a candidate-gene approach that identifies how
subtle variations in the genetic code can influence which blood pressure medication will work
most effectively. Recently, Geneticure has expanded their approach to additional chronic diseases and solving med-device variability, also driven by genetics.

Prior to Geneticure, Scott spent 10 years in entrepreneurial roles leading Target Corporation businesses in Minneapolis; most recently as director of a strategic advisory group for over $10 Billion of consumer categories including OTC pharmacy.